SABCS 2025

Important new data for young breast cancer patients

Firstline treatment of MBC: Which strategy is best?

Axilla dissection - less is more

AI based prognostic test

ALTTO trial outcome according to endocrine therapy

SERDs in early breast cancer - the new era has begun?

Surgery remains soc in low risk EBC

SERDs now in adjuvant therapy

Giredestrant will replace current adjuvant therapy

Revolution in adjuvant endocrine therapy?

PALLAS trial and ctDNA

sTILs with deep learning AI

Quality of live data DB11

Optimized endocrine therapy for premenopausal patients

Significant innovations in early and metastatic HER2+…

ctDNA analysis could optimize the approach in HER2+

Carboplatin in adjuvant setting of TNBC

Olaparib neoadjuvant with high PCR rates

In addition to pCR, ctDNA is prognostically relevant…

SERDy we wczesnym raku piersi -początek nowej epoki?

Carboplatino nel contesto adiuvante del TNBC

Otimização da terapia: abordagens endócrinas em…

El análisis del ADN libre circulante podría optimizar…

Risultati dello studio ALTTO in base alla terapia…

ASCENT-07 a negative trial

Updated results of VIKTORIA-1

Palbociclib likely delays CNS progression

Triple-positive MBC: less chemotherapy, more endocrine…

Make a hot tumor out of a cold tumor

Phase 2 combination of elacestrant with everolimus or…

Elacestrant as oral endocrine backbone

Biomarker and clinical subgroup analysis of evERA…

Elacestrant is a good combination partner for HR+ HER2+…

Traditional chemotherapy should not be forgotten as…

The significance of SG is more clearly defined

Chemotherapy-free treatment: a promising therapeutic…

New evidence for oral SERDs

Tucatinib a new SERD in the adjuvant setting

Monitoring of ILD

Significant innovations in early and metastatic HER2+…

ctDNA Dynamics as a biomarker of response

Maintenance therapy HER2+ Tucatinib as a new option

Sem melhorias em relação à terapia padrão

Résultats actualisés de VIKTORIA-1

La dinamica del ctDNA come biomarcatore di risposta

Tucatinib, un nouveau SERD dans le cadre d'un…

Jeszcze nie czas na rezygnację z tradycyjnej…

Elacestrant come partner endocrino orale

Risultati aggiornati di VIKTORIA-1